tiprankstipranks
NightHawk Biosciences (DE:1HB)
FRANKFURT:1HB

NightHawk Biosciences Stock Analysis & Ratings

0 Followers

1HB Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€1.60 - €7.63
Previous Close€2.17
Volume0.00
Average Volume (3M)487.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta0.29
Next EarningsNov 14, 2022
EPS Forecast-€0.26
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)N/A
Shares Outstanding25,649,824
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume487
P/B Ratio0.62
P/S Ratio47.04
P/CF RatioN/A
P/FCF Ratio-1.70
Total Debt€1.63M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside265.25% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering1


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

1HB FAQ

What was NightHawk Biosciences’s price range in the past 12 months?
NightHawk Biosciences lowest stock price was €1.60 and its highest was €7.63 in the past 12 months.
    What is NightHawk Biosciences’s market cap?
    Currently, no data Available
    What is NightHawk Biosciences’s price target?
    The average price target for NightHawk Biosciences is €7.94. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is €7.94 ,the lowest forecast is €7.94. The average price target represents 265.25% Increase from the current price of €2.174.
      What do analysts say about NightHawk Biosciences?
      NightHawk Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is NightHawk Biosciences’s upcoming earnings report date?
        NightHawk Biosciences’s upcoming earnings report date is Nov 14, 2022 which is in 86 days.
          How were NightHawk Biosciences’s earnings last quarter?
          NightHawk Biosciences released its earnings results on Aug 10, 2022. The company reported -€0.397 earnings per share for the quarter, missing the consensus estimate of -€0.298 by -€0.099.
            Is NightHawk Biosciences overvalued?
            According to Wall Street analysts NightHawk Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does NightHawk Biosciences pay dividends?
              NightHawk Biosciences does not currently pay dividends.
              What is NightHawk Biosciences’s EPS estimate?
              NightHawk Biosciences’s EPS estimate is -€0.26.
                How many shares outstanding does NightHawk Biosciences have?
                Currently, no data Available
                What happened to NightHawk Biosciences’s price movement after its last earnings report?
                NightHawk Biosciences reported an EPS of -€0.397 in its last earnings report, missing expectations of -€0.298. Following the earnings report the stock price went up 1.035%.
                  Which hedge fund is a major shareholder of NightHawk Biosciences?
                  Currently, no hedge funds are holding shares in DE:1HB

                  ---

                  NightHawk Biosciences Stock Analysis

                  Smart ScoreUnderperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  2

                  Analyst Forecast

                  Moderate Buy
                  Average Price Target: €7.94

                  Blogger Sentiment

                  N/A
                  Currently Not Enough Data Available

                  Insider Transactions

                  N/A
                  Currently Not Enough Data Available

                  News Sentiment

                  Neutral
                  Bullish 50% Bearish 50%

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -66.50%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -34.45%
                  Trailing 12-Months
                  Asset Growth
                  -5.00%
                  Trailing 12-Months
                  The NightHawk Biosciences Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  NightHawk Biosciences

                  Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis